Skip to main
NTRA
NTRA logo

Natera (NTRA) Stock Forecast & Price Target

Natera (NTRA) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 41%
Buy 53%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Natera Inc is positioned for positive revenue growth, driven by increased demand for its Signatera product, which saw a significant sequential rise in clinical units, outpacing expectations. The company's gross margin guidance has been raised, suggesting healthy operational efficiency and a favorable outlook on average selling prices, bolstered by expectations of expanded reimbursement coverage in oncology. Additionally, the strong growth in new Signatera patient additions, alongside the promising clinical outcomes demonstrated in partnership with Genentech, underscores a robust market acceptance and potential for sustained financial performance.

Bears say

Natera faces significant financial challenges, primarily due to anticipated margin erosion resulting from in-network pricing reductions as more commercial payors join the market, which could broaden the total addressable market but diminish profitability. The company's ongoing cash burn and historic lack of profitability raise concerns about its financial viability, particularly if reimbursement for its tests is reduced or if it fails to secure adequate reimbursement rates. Additionally, competition from superior diagnostic tests and potential regulatory changes pose further risks that could adversely impact Natera's market position and financial performance.

Natera (NTRA) has been analyzed by 17 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 53% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Natera (NTRA) Forecast

Analysts have given Natera (NTRA) a Buy based on their latest research and market trends.

According to 17 analysts, Natera (NTRA) has a Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $196.24, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $196.24, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Natera (NTRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.